Therefore, Trim31-Rhbdf2 binding and the subsequent Rhbdf2 ubiquitination are required for and conduce to the mitigation of liver steatosis, insulin resistance, and liver inflammation triggered by hepatocyte Rhbdf2-MAP3K7 signaling. Here, TRIM31 is linked to fatty liver disease.